港股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

维立志博-B

56.500

-0.350-0.62%

成交量：84.30万

成交额：4,691.13万

市值：112.44亿

市盈率：-40.46

高：57.900

开：57.150

低：54.300

收：56.850

52周最高：97.500

52周最低：44.720

股本：1.99亿

香港流通股本：1.53亿

量比：1.70

换手率：0.55%

股息：- -

股息率：- -

每股收益(LYR):-1.396

净资产收益率：-27.61%

总资产收益率：-9.92%

市净率：7.70

市盈率(LYR):-40.46

市销率: 54.96

数据加载中...

总览公司新闻资讯公告

维立志博-B(09887)完成44,391,598股未上市股份转换为H股，已发行股本增至197,670,289股

维立志博-B(09887)存仓市值总计14.86亿港元股东将2584.62万股股票存入中国证券登记结算香港

维立志博-B5月股份变动月报表：股本维持不变

维立志博(09887.HK)维利信临床研究结果入选世界肺癌大会口头报告

阿斯达克财经

维立志博-B(09887)：受托人拟根据H股奖励计划收购最高5000万美元H股

智通财经网

维立志博-B授出信托人指令，以最高5000万美元购买H股作为奖励计划

港股异动 | 维立志博-B(09887)早盘涨超4% 维利信™治疗晚期肺外神经内分泌癌III期临床研究获批

维立志博-B(09887)：维利信™(PD-L1/4-1BB双特异性抗体奥帕替苏米单抗，LBL-024)治疗晚期肺外神经内分泌癌的III期临床研究获得CDE批准

一周港股牛熊榜 | 金辉控股飙152%领跑，京西国际、天岳先进升逾六成强势爆发

老虎资讯综合

维立志博-B(09887)：吴凤岚获委任为非执行董事

维立志博－Ｂ(09887)出现大手买入7.84万股，成交价$66.0，涉资517.44万

阿斯达克财经

维立志博-B(09887)就H股全流通获联交所授出上市批准

维立志博－Ｂ(09887)股价下跌5.04%，现价港币$71.6

阿斯达克财经

维立志博-B(09887)：中国证监会就H股全流通出具备案通知书及公司拟实施H股全流通计划

港股异动 | 维立志博-B(09887)尾盘涨近3% Dianthus正推进LBL-047临床开发

维立志博-B4月股份变动月报表，股本维持不变

港股公告掘金 | 天臣控股附属与地上铁签订备忘录拟设合资公司打造香港新能源充电换电网络首期建10座多功能换电站

维立志博-B(09887)：LBL-047优先开发干燥综合征、系统性红斑狼疮和皮肌炎临床适应症

【券商聚焦】广发证券维持维立志博-B(09887)“买入”评级指核心管线进展积极

港股异动 | 维立志博-B(09887)午后涨超4% 核心产品LBL-024上市在即展现重磅单品潜力

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/09887/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"09887","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09887\",,,,,undefined,":{"symbol":"09887","market":"HK","secType":"STK","nameCN":"维立志博-B","latestPrice":56.5,"timestamp":1780646952010,"preClose":56.85,"halted":0,"volume":843000,"delay":0,"changeRate":-0.006156552330694836,"floatShares":153000000,"shares":199000000,"eps":-1.3964695836107954,"marketStatus":"休市中","change":-0.35,"latestTime":"06-05 16:09:12","open":57.15,"high":57.9,"low":54.3,"amount":46911250,"amplitude":0.063325,"askPrice":56.5,"askSize":15200,"bidPrice":55.95,"bidSize":5700,"shortable":3,"etf":0,"ttmEps":-1.3583840495123194,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1780882200000},"marketStatusCode":7,"adr":0,"listingDate":1753372800000,"exchange":"SEHK","adjPreClose":56.85,"openAndCloseTimeList":[[1780623000000,1780632000000],[1780635600000,1780646400000]],"volumeRatio":1.7030399365595443,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09887\",,,,,undefined,":{"symbol":"09887","floatShares":153000000,"roa":"-9.92%","roe":"-27.61%","lyrEps":-1.39647,"volumeRatio":1.7030399365595443,"shares":199000000,"dividePrice":0,"high":57.9,"amplitude":0.063325,"preClose":56.85,"low":54.3,"week52Low":44.72,"pbRate":"7.70","psRate":"54.96","week52High":97.5,"institutionHeld":0,"latestPrice":56.5,"committee":-0.454545,"eps":-1.3964695836107954,"divideRate":0,"volume":843000,"delay":0,"ttmEps":-1.3583840495123194,"open":57.15,"prevYearClose":51,"prevWeekClose":61.3,"prevMonthClose":61.3,"prevQuarterClose":74,"fiveDayClose":61.3,"twentyDayClose":79.2,"sixtyDayClose":53.85},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/09887\",params:#limit:5,,,undefined,":[{"date":"2026-03-27","symbol":"09887","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774575000000,"name":null,"time":"","dateTimestamp":1774540800000,"actualEps":null},{"date":"2025-08-29","symbol":"09887","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756431000000,"name":null,"time":"","dateTimestamp":1756396800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"09887\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"09887\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.5,"hold":0.25,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":4,"updateTime":1780070400000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/09887\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"09887","date":"2026-06-04","current":-41.539118,"percent":0.571429,"low":-76.458084,"twenty":-44.683717,"median":-39.965338,"eighty":-33.979621,"high":-30.202688,"avg":-42.358504,"sd":10.684006,"marketCap":11306998830},"quantilePoints":[{"date":"2025-07-25","current":-39.760016,"twenty":-39.760016,"median":-39.760016,"eighty":-39.760016,"marketCap":12652000240},{"date":"2025-08-01","current":-42.800562,"twenty":-46.836196,"median":-44.399434,"eighty":-42.800562,"marketCap":13535375000},{"date":"2025-08-08","current":-41.931377,"twenty":-45.734702,"median":-43.894587,"eighty":-42.800562,"marketCap":13293671875},{"date":"2025-08-15","current":-42.360797,"twenty":-44.683717,"median":-42.975881,"eighty":-41.70245,"marketCap":13409689375},{"date":"2025-08-22","current":-41.268557,"twenty":-45.0887,"median":-43.050098,"eighty":-41.70245,"marketCap":13022964375},{"date":"2025-08-29","current":-41.462871,"twenty":-44.683717,"median":-42.745269,"eighty":-41.268557,"marketCap":13146747980},{"date":"2025-09-05","current":-41.718992,"twenty":-44.115151,"median":-41.93996,"eighty":-40.603026,"marketCap":13087080440},{"date":"2025-09-12","current":-41.612383,"twenty":-43.894587,"median":-41.766832,"eighty":-40.253447,"marketCap":13077135850},{"date":"2025-09-19","current":-40.406926,"twenty":-43.894587,"median":-41.814673,"eighty":-40.270938,"marketCap":12689296840},{"date":"2025-09-26","current":-39.940552,"twenty":-43.592616,"median":-41.710721,"eighty":-39.940552,"marketCap":12510294220},{"date":"2025-10-03","current":-46.021818,"twenty":-44.124681,"median":-41.829747,"eighty":-40.190868,"marketCap":14449489270},{"date":"2025-10-10","current":-44.344385,"twenty":-44.480118,"median":-41.935668,"eighty":-40.263942,"marketCap":13902536820},{"date":"2025-10-17","current":-41.267963,"twenty":-44.480118,"median":-42.061577,"eighty":-40.352531,"marketCap":12927967000},{"date":"2025-10-24","current":-37.571928,"twenty":-44.331016,"median":-41.888099,"eighty":-40.263942,"marketCap":11774394560},{"date":"2025-10-31","current":-34.030535,"twenty":-44.258383,"median":-41.766832,"eighty":-39.846145,"marketCap":10680489660},{"date":"2025-11-07","current":-37.063837,"twenty":-44.143742,"median":-41.612383,"eighty":-39.421071,"marketCap":11625225710},{"date":"2025-11-14","current":-37.306884,"twenty":-44.026925,"median":-41.504614,"eighty":-38.171485,"marketCap":11734616200},{"date":"2025-11-21","current":-32.263354,"twenty":-43.773799,"median":-41.293984,"eighty":-37.626872,"marketCap":10143481800},{"date":"2025-11-28","current":-33.407237,"twenty":-43.416049,"median":-41.25873,"eighty":-37.278832,"marketCap":10541265400},{"date":"2025-12-05","current":-32.531883,"twenty":-43.110759,"median":-40.854935,"eighty":-36.232015,"marketCap":10282706060},{"date":"2025-12-12","current":-33.445348,"twenty":-43.033782,"median":-40.504976,"eighty":-34.804627,"marketCap":10590988350},{"date":"2025-12-19","current":-31.455565,"twenty":-42.962519,"median":-40.253447,"eighty":-33.697999,"marketCap":9984368360},{"date":"2025-12-24","current":-31.920084,"twenty":-42.892338,"median":-39.907071,"eighty":-33.445348,"marketCap":10163370980},{"date":"2026-01-02","current":-31.421623,"twenty":-42.818917,"median":-39.811672,"eighty":-33.24713,"marketCap":10044035900},{"date":"2026-01-09","current":-34.757237,"twenty":-42.712093,"median":-39.628079,"eighty":-33.303022,"marketCap":11137940800},{"date":"2026-01-16","current":-34.953981,"twenty":-42.570843,"median":-39.220132,"eighty":-33.387129,"marketCap":11237386700},{"date":"2026-01-23","current":-34.708884,"twenty":-42.534258,"median":-38.04671,"eighty":-33.234922,"marketCap":11147885390},{"date":"2026-01-30","current":-41.208386,"twenty":-42.402729,"median":-37.93488,"eighty":-33.285275,"marketCap":13295916830},{"date":"2026-02-06","current":-38.552413,"twenty":-42.362692,"median":-38.04671,"eighty":-33.303022,"marketCap":12470515860},{"date":"2026-02-13","current":-37.506904,"twenty":-42.335079,"median":-38.011119,"eighty":-33.387129,"marketCap":12202011930},{"date":"2026-02-20","current":-39.795685,"twenty":-42.275235,"median":-38.202679,"eighty":-33.413439,"marketCap":12927967000},{"date":"2026-02-27","current":-37.9711,"twenty":-42.061223,"median":-38.358648,"eighty":-33.438876,"marketCap":12470515860},{"date":"2026-03-06","current":-32.876582,"twenty":-42.035836,"median":-37.973315,"eighty":-33.326804,"marketCap":10710323430},{"date":"2026-03-13","current":-37.800338,"twenty":-41.938243,"median":-37.9711,"eighty":-33.411645,"marketCap":12371069960},{"date":"2026-03-20","current":-39.652105,"twenty":-41.914066,"median":-38.162788,"eighty":-33.431073,"marketCap":12927967000},{"date":"2026-03-27","current":-45.563334,"twenty":-41.938243,"median":-38.422097,"eighty":-33.438876,"marketCap":14817439100},{"date":"2026-04-02","current":-73.055706,"twenty":-42.061577,"median":-38.676054,"eighty":-33.441386,"marketCap":17572695150},{"date":"2026-04-10","current":-74.98239,"twenty":-42.364587,"median":-38.815397,"eighty":-33.443763,"marketCap":18175244000},{"date":"2026-04-17","current":-69.940613,"twenty":-42.73421,"median":-39.081216,"eighty":-33.482556,"marketCap":16960268450},{"date":"2026-04-24","current":-67.940785,"twenty":-43.090538,"median":-39.261059,"eighty":-33.558052,"marketCap":16476253800},{"date":"2026-04-30","current":-65.13036,"twenty":-44.026925,"median":-39.582143,"eighty":-33.605745,"marketCap":15804560000},{"date":"2026-05-08","current":-55.847576,"twenty":-44.547984,"median":-39.760016,"eighty":-33.640661,"marketCap":16030679080},{"date":"2026-05-15","current":-43.849045,"twenty":-45.37348,"median":-39.795589,"eighty":-33.697999,"marketCap":12619684710},{"date":"2026-05-22","current":-44.434352,"twenty":-44.931837,"median":-39.87359,"eighty":-33.778461,"marketCap":12758908970},{"date":"2026-05-29","current":-42.313126,"twenty":-44.693978,"median":-39.965338,"eighty":-33.850015,"marketCap":12192067340},{"date":"2026-06-04","current":-39.174736,"twenty":-44.683717,"median":-39.965338,"eighty":-33.979621,"marketCap":11306998830}],"updateTime":1780668199668},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"09887\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1185914600","title":"维立志博-B(09887)完成44,391,598股未上市股份转换为H股，已发行股本增至197,670,289股","url":"https://stock-news.laohu8.com/highlight/detail?id=1185914600","media":"公告速递","labels":["SGX"],"top":1,"itemType":null,"share":"https://ttm.financial/m/news/1185914600?lang=zh_cn&edition=fundamental","pubTime":"2026-06-05 19:30","pubTimestamp":1780659015,"startTime":"0","endTime":"0","summary":"2026年6月5日，维立志博-B(09887)发布翌日披露报表，宣布公司于2026年6月4日将44,391,598股未上市股份转换为H股。根据公告，这部分转换股份约占转换前公司已发行股本（不包括库存股份）153,278,691股的28.96%，本次变动后，公司于香港联交所上市的H股总数增至197,670,289股。\n同时，公告显示，对应未上市股份数量由原先的45,613,109股降至1,221,511股，此次转换股数占该部分未上市股份变动金额的比例约为97.32%。\n公司在公告中确认已取得董事会正式授权，且相关转换符合所有适用的上市规则与法律法规。公告由联席公司秘书左洪刚签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"维立志博-B(09887)完成44,391,598股未上市股份转换为H股，已发行股本增至197,670,289股","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641193294","title":"维立志博-B(09887)存仓市值总计14.86亿港元 股东将2584.62万股股票存入中国证券登记结算香港","url":"https://stock-news.laohu8.com/highlight/detail?id=2641193294","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641193294?lang=zh_cn&edition=fundamental","pubTime":"2026-06-05 08:11","pubTimestamp":1780618293,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，6月4日，维立志博-B(09887)出现仓位异动，存仓市值总计14.86亿港元，占比16.86%。该公司股东将2584.62万股股票存入中国证券登记结算香港，持股比例减少59.44%。5月20日，维立志博发布公告，公司已指示受托人根据H股奖励计划规则，利用总金额最高5000万美元的计划资金按当时的市价通过公开市场交易购入额外H股。受托人过往已根据H股奖励计划规则按公司指示于2025年通过公开市场交易购入若干H股。上述购入的目标股份将用作在H股奖励计划项下相关归属条件达成时授予受让人的奖励股份来源。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450494.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","HK0000252160.HKD","HK0000500386.USD","HK0000252152.HKD","09887","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105301071","title":"维立志博-B5月股份变动月报表：股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1105301071","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105301071?lang=zh_cn&edition=fundamental","pubTime":"2026-06-01 17:35","pubTimestamp":1780306558,"startTime":"0","endTime":"0","summary":"2026年6月1日，南京维立志博生物科技有限公司发布2026年5月股份变动月报表。公告显示，截至2026年5月31日，公司已发行股份数量及注册股本均保持稳定，未发生新增发行、回购或注销等变动事项。维立志博-B确认已遵照香港联交所《上市规则》及适用法律法规的要求，公告由公司联席公司秘书左洪刚签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638651160","title":"维立志博(09887.HK)维利信临床研究结果入选世界肺癌大会口头报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2638651160","media":"阿斯达克财经","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638651160?lang=zh_cn&edition=fundamental","pubTime":"2026-05-28 12:10","pubTimestamp":1779941400,"startTime":"0","endTime":"0","summary":"维立志博-B(09887.HK) 公布，评估维利信(PD-L1/4-1BB双特异性抗体奥帕替苏米单抗，LBL-024)联合化疗用于治疗一线非小细胞肺癌(NSCLC)的II期临床研究结果入选将于9月12至15日举行的2026年世界肺癌大会(WCLC)口头报告。公司将基于较此前已披露的18例患者数据显著扩大的样本量，展示奥帕替苏米单抗在一线NSCLC中的突破性疗效。(jl/da)(港股报价延迟最少十五分钟。沽空资料截至 2026-05-27 16:25。)AASTOCKS新闻","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20250721150110069_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20250721150110069_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1526453/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1526453/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["09887","HK0000252160.HKD","HK0000252152.HKD","HK0000500386.USD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636584978","title":"维立志博-B(09887)：受托人拟根据H股奖励计划收购最高5000万美元H股","url":"https://stock-news.laohu8.com/highlight/detail?id=2636584978","media":"智通财经网","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636584978?lang=zh_cn&edition=fundamental","pubTime":"2026-05-20 19:15","pubTimestamp":1779275740,"startTime":"0","endTime":"0","summary":"维立志博-B(09887)发布公告，公司已指示受托人根据H股奖励计划规则，利用总金额最高5000万美元的计划资金按当时的市价通过公开市场交易购入额外H股。受托人过往已根据H股奖励计划规则按公司指示于2025年通过公开市场交易购入若干H股。上述购入的目标股份将用作在H股奖励计划项下相关归属条件达成时授予受让人的奖励股份来源。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_27.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_27.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444077.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["HK0000500386.USD","BK1161","09887","HK0000252160.HKD","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174158628","title":"维立志博-B授出信托人指令，以最高5000万美元购买H股作为奖励计划","url":"https://stock-news.laohu8.com/highlight/detail?id=1174158628","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174158628?lang=zh_cn&edition=fundamental","pubTime":"2026-05-20 19:13","pubTimestamp":1779275605,"startTime":"0","endTime":"0","summary":"维立志博-B已授权信托人根据其H股奖励计划，动用不超过5000万美元的资金在二级市场购买H股。\n该举措旨在为公司的股权激励计划提供股份来源，彰显管理层对长期发展的信心。通过信托人购股并持有，公司可在未来向符合资格的参与者授予股份奖励，以此绑定核心团队利益，推动公司价值持续增长。\n此次购股计划将按照相关市场规则及公司章程执行，具体购买时间、价格及数量将由信托人依据市场情况独立操作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","HK0000252160.HKD","HK0000500386.USD","09887","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636863428","title":"港股异动 | 维立志博-B(09887)早盘涨超4% 维利信™治疗晚期肺外神经内分泌癌III期临床研究获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2636863428","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636863428?lang=zh_cn&edition=fundamental","pubTime":"2026-05-19 09:53","pubTimestamp":1779155590,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，维立志博-B早盘涨超4%，截至发稿，涨3.21%，报64.35港元，成交额897.51万港元。消息面上，5月19日，维立志博-B发布公告，中华人民共和国国家药品监督管理局药品审评中心已批准开展评价维利信联合含铂化疗作为一线治疗在晚期肺外神经内分泌癌患者中的确证性III期临床研究。该研究获批是基于奥帕替苏米单抗在Ib/II期概念验证性研究中所展现的突破性疗效与良好安全性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1443260.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["III","BK1161","HK0000252160.HKD","HK0000500386.USD","BK4588","BK4134","VXUS","BK4585","09887","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636022270","title":"维立志博-B(09887)：维利信™(PD-L1/4-1BB双特异性抗体奥帕替苏米单抗，LBL-024)治疗晚期肺外神经内分泌癌的III期临床研究获得CDE批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2636022270","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636022270?lang=zh_cn&edition=fundamental","pubTime":"2026-05-19 07:18","pubTimestamp":1779146304,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B 发布公告，中华人民共和国国家药品监督管理局药品审评中心已批准开展评价维利信联合含铂化疗作为一线治疗在晚期肺外神经内分泌癌患者中的确证性III期临床研究。该研究获批是基于奥帕替苏米单抗在Ib/II期概念验证性研究中所展现的突破性疗效与良好安全性。奥帕替苏米单抗已在肺外神经内分泌癌、非小细胞肺癌、小细胞肺癌及胆道癌四个适应症的注册性或II 期临床试验中展示出全球首创或同类最优潜力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1443206.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","LU1169589451.USD","LU1169590202.USD","BK4023","HK0000500386.USD","LU1223082196.USD","HK0000252152.HKD","PD","HK0000252160.HKD","09887","CDE","LU1223082519.USD","LU1223083913.SGD","BK4134","III","BK4017"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178121731","title":"一周港股牛熊榜 |  金辉控股飙152%领跑，京西国际、天岳先进升逾六成强势爆发","url":"https://stock-news.laohu8.com/highlight/detail?id=1178121731","media":"老虎资讯综合","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178121731?lang=zh_cn&edition=fundamental","pubTime":"2026-05-15 17:43","pubTimestamp":1778838189,"startTime":"0","endTime":"0","summary":"今日股价显著放量，收盘升205%，成交额超10亿港元。京西国际于5月10日晚间发布公告，披露控股股东京西智行集团告知，其与立讯精密订立买卖协议，立讯精密将收购京西智行集团全部股权，从而间接持有京西国际约59.50%股份，有望成为其最终控股股东。次日股价再升约13.60%，两个交易日累计升逾60%。受金价回软拖累，港股黄金股板块普遍走弱，灵宝黄金本周跌幅逾20%，领跌黄金板块。","market":"hk","thumbnail":"https://community-static.tradeup.com/news/549ed9c19f16d97443cb9ffadc6a6514","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/549ed9c19f16d97443cb9ffadc6a6514"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"b8ee1f948934007dbda4ac7ad69286fb","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09900","02339","09993","00068","09887","00326","02658","01236","02631","03330"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2635076837","title":"维立志博-B(09887)：吴凤岚获委任为非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2635076837","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635076837?lang=zh_cn&edition=fundamental","pubTime":"2026-05-15 17:16","pubTimestamp":1778836605,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B(09887)发布公告，吴凤岚博士已获委任为公司非执行董事，自2026年5月15日起生效及至第一届董事会任期届满为止，且根据公司的章程，吴博士合资格在其任期届满后于股东会上重选连任。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1442264.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000252152.HKD","HK0000252160.HKD","HK0000500386.USD","09887","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635698775","title":"维立志博－Ｂ(09887)出现大手买入7.84万股，成交价$66.0，涉资517.44万","url":"https://stock-news.laohu8.com/highlight/detail?id=2635698775","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635698775?lang=zh_cn&edition=fundamental","pubTime":"2026-05-15 09:55","pubTimestamp":1778810100,"startTime":"0","endTime":"0","summary":"[大手成交]维立志博－Ｂ(09887)在上午09:55出现大手买入，成交量为7.84万，成交价为港币$66.0，涉资517.44万。至目前为止，股价跌3.796%，今日最高价为$68.8，而最低价为$65.85，总成交量为20.12万股，总成交金额港币$1.333千万。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180416150431576_s.png","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180416150431576_s.png"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2605153096/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2605153096/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["09887","HK0000252152.HKD","HK0000500386.USD","HK0000252160.HKD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635748331","title":"维立志博-B(09887)就H股全流通获联交所授出上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2635748331","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635748331?lang=zh_cn&edition=fundamental","pubTime":"2026-05-14 21:10","pubTimestamp":1778764220,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B(09887)公布，公司已收到联交所于2026年5月14日所授出约4439.16万股H股上市及买卖的批准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441926.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","HK0000252160.HKD","HK0000500386.USD","IPOS","09887","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635527111","title":"维立志博－Ｂ(09887)股价下跌5.04%，现价港币$71.6","url":"https://stock-news.laohu8.com/highlight/detail?id=2635527111","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635527111?lang=zh_cn&edition=fundamental","pubTime":"2026-05-13 13:10","pubTimestamp":1778649000,"startTime":"0","endTime":"0","summary":"[下跌股]维立志博－Ｂ(09887) 股价在下午01:10比前收市价下跌5.04%，现股价为港币$71.6。至目前为止，今日最高价为$77.4，而最低价为$71.6。总成交量为43.13万股，总成交金额为港币$3.154千万。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180725131622959_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180725131622959_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2605132215/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2605132215/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["HK0000252152.HKD","HK0000252160.HKD","HK0000500386.USD","09887","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633245610","title":"维立志博-B(09887)：中国证监会就H股全流通出具备案通知书及公司拟实施H股全流通计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2633245610","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633245610?lang=zh_cn&edition=fundamental","pubTime":"2026-05-08 20:23","pubTimestamp":1778243033,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B 发布公告，公司已代表23名公司股东向中国证监会提交申请，有关23名股东所持合共4439.16万股未上市股份转换为H股。于2026年5月7日，公司收到中国证监会就H股全流通出具日期为2026年4月27日的《关于南京维立志博生物科技股份有限公司未上市股份“全流通”备案通知书》。根据备案通知书，若公司自备案通知书出具之日起12个月内未完成转换及上市，如拟继续推进，应当更新备案材料。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1439753.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"维立志博-B(09887)：中国证监会就H股全流通出具备案通知书及公司拟实施H股全流通计划","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09887","HK0000252160.HKD","BK1161","HK0000252152.HKD","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633480440","title":"港股异动 | 维立志博-B(09887)尾盘涨近3% Dianthus正推进LBL-047临床开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2633480440","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633480440?lang=zh_cn&edition=fundamental","pubTime":"2026-05-08 15:25","pubTimestamp":1778225156,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，维立志博-B尾盘涨近3%，截至发稿，涨2.65%，报81.3港元，成交额4950.42万港元。作为战略重点的核心管线资产，Dianthus正在推进LBL-047的临床开发，以验证其在SjD、SLE和DM三项存在高度未满足需求适应症中的临床价值。于2026年3月，Dianthus成功完成一轮扩大规模的包销公开发行，募集资金总额约7.19亿美元，为推进LBL-047的全球开发提供了坚实的资本保障。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1439488.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","VXUS","BK4585","09887","HK0000252152.HKD","HK0000500386.USD","HK0000252160.HKD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197737270","title":"维立志博-B4月股份变动月报表，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1197737270","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197737270?lang=zh_cn&edition=fundamental","pubTime":"2026-05-06 16:38","pubTimestamp":1778056698,"startTime":"0","endTime":"0","summary":"南京维立志博生物科技有限公司于2026年5月6日发布2026年4月股份变动月报表。公告显示，截至2026年4月30日，公司股本结构保持稳定，未有新增发行、购回或注销股份活动。本期已发行股份总数与上期持平，H股与其他未上市普通股数目均无变化，分别维持在153,278,691股和45,613,109股。截至本月底，维立志博-B的已发行股份总数仍保持在198,891,800股，符合香港联交所《上市规则》及相关法律法规的要求。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633799379","title":"港股公告掘金 | 天臣控股附属与地上铁签订备忘录 拟设合资公司打造香港新能源充电换电网络 首期建10座多功能换电站","url":"https://stock-news.laohu8.com/highlight/detail?id=2633799379","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633799379?lang=zh_cn&edition=fundamental","pubTime":"2026-05-06 09:08","pubTimestamp":1778029695,"startTime":"0","endTime":"0","summary":"重大事项：维立志博-B(09887)：LBL-047优先开发干燥综合征、系统性红斑狼疮和皮肌炎临床适应症歌礼制药-B(01672)将携多个项目数据亮相第33届欧洲肥胖症大会(ECO 2026)瑞博生物-B(06938)与勃林格殷格翰的研发合作达成关键里程碑先声药业(02096)：SIM0613(LRRC15抗体偶联药物)获国家药品监督管理局签发药物临床试验批准通知书医渡科技(02158)附属成功中","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1438306.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09887","BK4588","HK0000252152.HKD","HK0000252160.HKD","01672","HK0000500386.USD","VXUS","06938","BK1515","000941.SH","BK1574","01201","159875","160640","BK1161","BK4585","399941","BK1116"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633976162","title":"维立志博-B(09887)：LBL-047优先开发干燥综合征、系统性红斑狼疮和皮肌炎临床适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=2633976162","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633976162?lang=zh_cn&edition=fundamental","pubTime":"2026-05-06 08:40","pubTimestamp":1778028013,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B 发布公告，其合作伙伴Dianthus Therapeutics已选定干燥综合征、系统性红斑狼疮和皮肌炎作为LBL-047临床开发的首批三项优先适应症。作为战略重点的核心管线资产，Dianthus正在推进LBL-047的临床开发，以验证其在SjD、SLE和DM三项存在高度未满足需求适应症中的临床价值。于2025年10月16日，本公司与Dianthus达成独家全球合作伙伴关系，交易总金额最高可达10亿美元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1438295.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"维立志博-B(09887)：LBL-047优先开发干燥综合征、系统性红斑狼疮和皮肌炎临床适应症","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","HK0000252160.HKD","HK0000252152.HKD","09887","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630498361","title":"【券商聚焦】广发证券维持维立志博-B(09887)“买入”评级 指核心管线进展积极","url":"https://stock-news.laohu8.com/highlight/detail?id=2630498361","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630498361?lang=zh_cn&edition=fundamental","pubTime":"2026-04-27 17:08","pubTimestamp":1777280907,"startTime":"0","endTime":"0","summary":"报告认为，BD收入助力业绩改善，2025年全年实现收入1.77亿元，主要来自LBL-047对外授权首付款及里程碑款；研发开支2.89亿元，亏损由2024年的3.01亿元收窄至2.11亿元。广发证券持续看好公司核心产品竞争力，采取风险调整DCF法得到合理价值为110.96港元/股，维持“买入”评级。","market":"other","thumbnail":"https://static.szfiu.com/news/20250109/ODYzMTA4NTI1Nzg5MjIw.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODYzMTA4NTI1Nzg5MjIw.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1980013","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887","01776"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630635700","title":"港股异动 | 维立志博-B(09887)午后涨超4% 核心产品LBL-024上市在即 展现重磅单品潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=2630635700","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630635700?lang=zh_cn&edition=fundamental","pubTime":"2026-04-27 14:52","pubTimestamp":1777272738,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，维立志博-B午后涨超4%，截至发稿，涨2.28%，报85.3港元，成交额3735.49万港元。消息面上，维立志博近日宣布，公司自主研发的PD-L1/4-1BB双特异性抗体维利信联合用药一线治疗局部晚期或转移性胃或胃食管结合部腺癌的Ⅱ期临床研究顺利完成首例患者入组。兴业证券则表示，LBL-024 上市在即展现重磅单品潜力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1434297.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","HK0000500386.USD","IPOS","09887","HK0000252160.HKD","VXUS","BK4585","HK0000252152.HKD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":1,"totalSize":126,"code":"91000000","status":"200"}]}}